ANNEXON, INC. Financing Cash Flow
ANNEXON, INC. (ANNX) reported Financing Cash Flow of $65.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- ANNEXON, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $32.10M, a 20883.01% increase year-over-year.
- ANNEXON, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $32.90M, a 55655.93% increase year-over-year.
- ANNEXON, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $95.08M, a 1814.21% increase year-over-year.
- ANNEXON, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $13.56M, a 7650.86% increase year-over-year.
- ANNEXON, INC. net cash provided by (used in) financing activities for fiscal 2025 was $108.86M, a 32.47% decline from fiscal 2024.
- ANNEXON, INC. net cash provided by (used in) financing activities for fiscal 2024 was $161.21M, a 18.95% increase from fiscal 2023.
- ANNEXON, INC. net cash provided by (used in) financing activities for fiscal 2023 was $135.52M, a 10.26% increase from fiscal 2022.
- ANNEXON, INC. net cash provided by (used in) financing activities for fiscal 2022 was $122.91M, a 6747.24% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $65.00M 10-Q · filed 2026-08-12 | $160.08M derived: sum of 3 quarters · filed 2026-08-12 | $173.64M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $32.90M 10-Q · filed 2026-05-07 | $127.97M derived: sum of 2 quarters · filed 2026-05-07 | $141.54M derived: sum of 3 quarters · filed 2026-05-07 | $141.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $95.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $108.64M derived: sum of 2 quarters · filed 2026-03-30 | $108.80M derived: sum of 3 quarters · filed 2026-08-12 | $108.86M 10-K · filed 2026-03-30 |
| 2025-09-30 | $13.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $13.72M derived: sum of 2 quarters · filed 2026-08-12 | $13.78M 10-Q · filed 2025-11-10 | $18.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $212.00K 10-Q · filed 2026-08-12 | $5.18M derived: sum of 3 quarters · filed 2026-08-12 | $5.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $59.00K 10-Q · filed 2026-05-07 | $5.03M derived: sum of 2 quarters · filed 2026-05-07 | $5.20M derived: sum of 3 quarters · filed 2026-05-07 | $128.85M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.14M derived: sum of 2 quarters · filed 2026-03-30 | $128.79M derived: sum of 3 quarters · filed 2026-03-30 | $161.21M 10-K · filed 2026-03-30 |
| 2024-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $123.83M derived: sum of 2 quarters · filed 2025-11-10 | $156.24M 10-Q · filed 2025-11-10 | $273.84M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $123.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $156.06M 10-Q · filed 2025-08-14 | $273.66M derived: sum of 3 quarters · filed 2025-08-14 | $273.66M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $32.41M 10-Q · filed 2025-05-12 | $150.01M derived: sum of 2 quarters · filed 2025-05-12 | $150.01M derived: sum of 3 quarters · filed 2025-05-12 | $150.35M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $117.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $117.60M derived: sum of 2 quarters · filed 2025-03-03 | $117.94M derived: sum of 3 quarters · filed 2025-03-03 | $135.52M 10-K · filed 2025-03-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $345.00K derived: sum of 2 quarters · filed 2024-11-14 | $17.93M 10-Q · filed 2024-11-14 | $18.03M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $345.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $17.93M 10-Q · filed 2024-08-12 | $18.03M derived: sum of 3 quarters · filed 2024-08-12 | $140.70M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $17.58M 10-Q · filed 2024-05-13 | $17.69M derived: sum of 2 quarters · filed 2024-05-13 | $140.36M derived: sum of 3 quarters · filed 2024-05-13 | $140.47M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $122.78M derived: sum of 2 quarters · filed 2024-03-26 | $122.89M derived: sum of 3 quarters · filed 2024-03-26 | $122.91M 10-K · filed 2024-03-26 |
| 2022-09-30 | $122.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $122.78M derived: sum of 2 quarters · filed 2023-11-13 | $122.80M 10-Q · filed 2023-11-13 | $123.75M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $132.00K 10-Q · filed 2023-08-07 | $1.08M derived: sum of 3 quarters · filed 2023-08-07 | $1.01M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $19.00K 10-Q · filed 2023-05-08 | $967.00K derived: sum of 2 quarters · filed 2023-05-08 | $894.00K derived: sum of 3 quarters · filed 2023-05-08 | $1.55M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $948.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $875.00K derived: sum of 2 quarters · filed 2023-03-06 | $1.53M derived: sum of 3 quarters · filed 2023-03-06 | $1.79M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $579.00K derived: sum of 2 quarters · filed 2022-11-03 | $847.00K 10-Q · filed 2022-11-03 | $847.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $652.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $920.00K 10-Q · filed 2022-08-08 | $920.00K derived: sum of 3 quarters · filed 2022-08-08 | $260.70M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $268.00K 10-Q · filed 2022-05-09 | $268.00K derived: sum of 2 quarters · filed 2022-05-09 | $260.05M derived: sum of 3 quarters · filed 2022-05-09 | $361.71M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $259.78M derived: sum of 2 quarters · filed 2022-03-01 | $361.45M derived: sum of 3 quarters · filed 2022-03-01 | $360.88M 10-K · filed 2022-03-01 |
| 2020-09-30 | $259.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $361.45M derived: sum of 2 quarters · filed 2021-11-09 | $360.88M 10-Q · filed 2021-11-09 | $360.03M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $101.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $101.09M 10-Q · filed 2021-08-16 | $100.25M derived: sum of 3 quarters · filed 2021-08-16 | $129.49M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$571.00K 10-Q · filed 2021-05-17 | -$1.42M derived: sum of 2 quarters · filed 2021-05-17 | $27.82M derived: sum of 3 quarters · filed 2021-05-17 | |
| 2019-12-31 | -$846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $28.39M derived: sum of 2 quarters · filed 2021-03-25 | $28.39M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $29.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $29.24M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $3.00K 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |